Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 23 2023 - 9:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 23, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 23 October 2023 – On 10 August 2023, Novo Nordisk
initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This
programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning
1 February 2023.
Under the programme initiated 10 August 2023, Novo Nordisk will repurchase B
shares for an amount up to DKK 5.7 billion in the period from 10 August 2023 to 31 October 2023.
Since the announcement 16 October 2023, the following transactions have been made:
Number of B shares
(of DKK 0.10) |
Average
purchase price |
Transaction value,
DKK |
Accumulated, last announcement |
6,993,162 |
|
4,548,993,033 |
16 October 2023 |
145,000 |
720.34 |
104,449,422 |
17 October 2023 |
145,000 |
717.25 |
104,000,773 |
18 October 2023 |
135,000 |
711.82 |
96,095,956 |
19 October 2023 |
140,000 |
703.40 |
98,475,655 |
20 October 2023 |
145,000 |
687.35 |
99,665,731 |
Accumulated under the programme |
7,703,162 |
|
5,051,680,570 |
The details for each transaction made under the share repurchase programme are
published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 40,196,846 B shares of DKK
0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares of DKK 0.10 in the company
is 4,510,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 30 billion
during a 12- month period beginning 1 February 2023. As of 20 October 2023, Novo Nordisk has since 1 February 2023 repurchased a total
of 36,140,324 B shares of DKK 0.10 at an average share price of DKK 562.83 per B share of DKK 0.10 equal to a transaction value of DKK
20,340,911,156.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 59,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram,
X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
|
|
Sina Meyer
+45 3075 6656
azey@novonordisk.com |
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 66 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: October 23, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Aug 2023 to Aug 2024